Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 29;6(4):1953-85.
doi: 10.3390/cancers6041953.

The future of glioblastoma therapy: synergism of standard of care and immunotherapy

Mira A Patel  1 , Jennifer E Kim  2 , Jacob Ruzevick  3 , Gordon Li  4 , Michael Lim  5
Affiliations
Review

The future of glioblastoma therapy: synergism of standard of care and immunotherapy

Mira A Patel et al. Cancers (Basel). .

Abstract

The current standard of care for glioblastoma (GBM) is maximal surgical resection with adjuvant radiotherapy and temozolomide (TMZ). As the 5-year survival with GBM remains at a dismal <10%, novel therapies are needed. Immunotherapies such as the dendritic cell (DC) vaccine, heat shock protein vaccines, and epidermal growth factor receptor (EGFRvIII) vaccines have shown encouraging results in clinical trials, and have demonstrated synergistic effects with conventional therapeutics resulting in ongoing phase III trials. Chemoradiation has been shown to have synergistic effects when used in combination with immunotherapy. Cytotoxic ionizing radiation is known to trigger pro-inflammatory signaling cascades and immune activation secondary to cell death, which can then be exploited by immunotherapies. The future of GBM therapeutics will involve finding the place for immunotherapy in the current treatment regimen with a focus on developing strategies. Here, we review current GBM therapy and the evidence for combination of immune checkpoint inhibitors, DC and peptide vaccines with the current standard of care.

PubMed Disclaimer

References

    1. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin. Oncol. 2003;30:10–14. - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. - PubMed
    1. DeAngelis L.M. Brain tumors. N. Engl. J. Med. 2001;344:114–123. - PubMed
    1. Walker M.D., Alexander E., Hunt W.E., MacCarty C.S., Mahaley S.M., Mealey J., Norrell H., Owens G., Ransohoff J., Wilson C.B., Gehan E.A., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurg. 1978;49:333–343. - PubMed
    1. Walker M.D., Green S.B., Byar D.P., Alexander E., Batzdorf U., Brooks W.H., Hunt W.E., MacCarty C.S., Mahaley S.M., Mealey J., et al. Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 1980;303:1323–1329. - PubMed